[May 23, 2017] |
|
Baxter Presents Data at ISPOR Annual Meeting with Focus on Helping Hospitals Improve Patient Care
Baxter International Inc. (NYSE: BAX), a global medical products
company, presented data from seven health economic and cost studies at
the International Society for Pharmacoeconomics and Outcomes Research
(ISPOR) annual meeting this week. The data covered four critical areas
of patient care - kidney disease, hospital malnutrition, medication
delivery and surgery.
"Baxter is committed to providing real-world information that hospitals
and health systems can use to make decisions that help to further
improve patient care," said Halit Bander, vice president of clinical and
health economic and outcomes research for Baxter. "As one of the largest
of its kind, ISPOR is an important opportunity for leaders like Baxter
to contribute new data around the economic impact of critical treatment
options."
Among the data being presented:
Kidney Disease
-
A cost consequence analysis concluded that Baxter's RTS Disease
Management Model in Colombia, from the payer perspective, is a
cost-saving alternative to other existing treatment models based on
improved hospitalization outcomes and mortality in dialysis patients.
In one year of follow up, related hospitalization costs in Colombia
could be reduced by almost 20 percent with the RTS Disease Management
Model. Assuming a base case population of 2,500 patients, the model
could potentially reduce costs by more than US$1.6 million in one
year. (PHS176 - Cost Consequence Analysis of a Renal Disease
Management Model Currently Implemented in a Colombian Payer)
-
A study describing the hospital costs as well as the clinical and
demographic drivers of patients currently treated through the RTS
Disease Management Model in Colombia found the average cost of one
hospital visit for one of these dialysis patients could be around
US$2,500. The results provide a better understanding of costs
associated with the RTS patient population and may help lead to the
development on different risk profiles based on patient
characteristics (e.g., diabetes, anemia). (PHS190 - Prediction of
Hospitalization Cost in Dialysis Patients)
-
Under the best available cost information, results of a budget impact
model demonstrated the potential for several billion yen in cost
savings for the Japanese government if the number of patients treated
with peritoneal dialysis is increased from 3 percent in 2016 to more
than 20 percent in 2020 versus treated with in-center hemodialysis.
The model incorporates estimates for the dialysis patient population
in five years and associated costs collected by a well-established
data source for epidemiological and pharmacoeconomic studies in Japan. (PUK9
- A Budget Impact Analysis of Increasing Peritoneal Dialysis (PD) in
Japan)
Hospital Malnutrition
-
A budget impact analysis shows that using Baxter's NUMETA ready-to-use
pediatric parenteral nutrition (PN) could provide an overall positive
impact on pediatric PN budgets in Colombian hospitals. Assuming a base
case population of 24,000 patients treated with PN, savings driven by
a progressive adoption of NUMETA could range between US$1.6 million
and US$3 million in a three-year period. The data was derived from a
model that took into account all necessary PN compounding resources,
such as ingredients, consumables, device costs and staff time. The
model also looked at costs associated with medication errors and blood
stream infections, which were demonstrated to be important drivers of
cost. (PIH15 - NUMETA Budget-Impact Model for Pediatric Parenteral
Nutrition)
Medication Delivery
-
Research has shown the use of smart infusion pumps reduces drug
administration errors by 80 to 95 percent. A technology assessment
suggested that using smart pumps for intravenous drug administration
in non-critical settings compared to standard infusion pumps could be
an effective technology to not only help avoid medication errors, but
also reduce adverse events, improve medication adherence and enhance
convenience for clinicians. (PMD115 - Technology Assessment of the
Effectiveness and Convenience of Smart Pumps in Non Critical
Hospitalary Settings)
Surgery
-
A systematic literature review analysis assessed the clinical and
economic burden associated with bleeding during cardiac surgery, and
observed that patients with bleeding had higher mortality rates versus
patients without bleeding (perioperative mortality 21 percent versus 5
percent; 30-day mortality 22 percent versus 5.5 percent). Results also
showed significantly higher overall per-patient costs for those who
experienced a bleeding-related complication and/or transfusion. (PCV111
- Clinical and Economic Burden of Bleeding in Cardiac Surgery: A
Systematic Review)
-
A systematic review analysis of published literature assessed the
clinical and economic burden associated with transfusions used during
and after cardiac surgery. Data indicates transfusion use may be
associated with negative effects on patient discharge status,
long-term complication rate (90.4 percent for transfusion patients
versus 82.99 percent for non-transfused patients) and mortality rate
(5.8 percent for transfusion patients versus 3.3 percent for
non-transfused patients). Results indicate that widespread adoption of
strategies and procedures that reduce the risk of post-operative
bleeding, and therefore the need for blood transfusion, may reduce
both the clinical and economic burdens of transfusion. (PCV110 -
Clinical and Economic Burden of Transfusion in Cardiac Surgery: A
Systematic Review)
Abstracts for the seven healthcare use, policy and cost studies are
available in the ISPOR
Scientific Presentations Database.
About Baxter
Baxter provides a broad portfolio of essential renal and hospital
products, including home, acute and in-center dialysis; sterile IV
solutions; infusion systems and devices; parenteral nutrition;
biosurgery products and anesthetics; and pharmacy automation, software
and services. The company's global footprint and the critical nature of
its products and services play a key role in expanding access to
healthcare in emerging and developed countries. Baxter's employees
worldwide are building upon the company's rich heritage of medical
breakthroughs to advance the next generation of healthcare innovations
that enable patient care.
This release includes forward-looking statements concerning
anticipated benefits associated with the use of Baxter's RTS Disease
Management Model, NUMETA product, smart infusion pumps and procedures
that reduce the risk of post-operative bleeding complications. The
statements are based on assumptions about many important factors,
including the following, which could cause actual results to differ
materially from those in the forward-looking statements: the
applicability of the studies to related cost savings estimates (as
described above in "-Kidney Disease," "-Hospital Malnutrition,"
"-Medication Delivery" and "-Surgery"); satisfaction of regulatory and
other requirements; actions of regulatory bodies and other governmental
authorities; product quality, manufacturing or supply, or patient safety
issues; changes in law and regulations; and other risks identified in
Baxter's most recent filing on Form 10-K and other SEC (News - Alert) filings, all of
which are available on Baxter's website. Baxter does not undertake to
update its forward-looking statements.
Baxter and NUMETA are registered trademarks of Baxter International Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170523005830/en/
[ Back To TMCnet.com's Homepage ]
|